Compass Therapeutics (CMPX) said Tuesday topline data from an ongoing phase 2/3 trial of tovecimig combined with paclitaxel in biliary tract cancer showed 'statistically significant' improvement in overall response rate, indicating it has met the trial's primary efficacy endpoint.
The drug combination achieved a 17.1% ORR, including one complete response, versus 5.3% for paclitaxel alone.
The secondary endpoints including progression-free survival, overall survival, and duration of response-could not be analyzed yet due to insufficient events, with data expected in Q4, the company said.
Shares rose 11% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.